Statistiche di base
| LEI | 529900F018DMYWH38923 |
| CIK | 744218 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Celldex Therapeutics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 7, 2026 |
Celldex Reports First Quarter Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports First Quarter Financial Results and Provides Corporate Update Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na |
|
| April 29, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2026 |
28AUG200910022691 Proxy Statement for 2026 Annual Meeting 2025 Annual Report on Form 10-K 6NoticeofAnnualMeetingofStockholders DateandTime VirtualMeeting RecordDate June25,2026 at 9:00a. |
|
| April 2, 2026 |
Exhibit 1.1 CELLDEX THERAPEUTICS, INC. 10,345,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement April 1, 2026 LEERINK PARTNERS LLC TD SECURITIES (USA) LLC As Representatives of the several Underwriters c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Ge |
|
| April 2, 2026 |
Celldex Announces Pricing of $300 Million Public Offering of Common Stock Exhibit 99.2 Celldex Announces Pricing of $300 Million Public Offering of Common Stock HAMPTON, N.J., April 1, 2026 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares to be sold in the offeri |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| April 2, 2026 |
Celldex Announces Proposed Public Offering of Common Stock Exhibit 99.1 Celldex Announces Proposed Public Offering of Common Stock HAMPTON, N.J., April 1, 2026 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In addition, Celldex expects to grant the underwriters a 30-day option to purchase up to an add |
|
| April 2, 2026 |
Calculation of Filing Fee Tables S-3 Celldex Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| April 2, 2026 |
10,345,000 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-275300 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2023) 10,345,000 Shares of Common Stock We are offering 10,345,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CLDX.” The last reported sale price of our common stock on April 1, |
|
| April 1, 2026 |
SUBJECT TO COMPLETION, DATED APRIL 1, 2026 TABLE OF CONTENTS The information in this preliminary prospectus is not complete and may be changed. |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.9 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Anthony S. Marucci (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.16 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Diane Young, M.D. (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E |
|
| February 25, 2026 |
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exa |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.10 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Sam Martin (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E T H: WH |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.11 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Tibor Keler, Ph.D. (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.13 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Sarah Cavanaugh (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E T |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.14 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Margo Heath-Chiozzi, M.D. (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.15 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Elizabeth Crowley (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E |
|
| February 25, 2026 |
SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100% |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.17 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Freddy Jimenez (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E T H |
|
| February 25, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.12 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 8, 2025 (the “Effective Date”), between Ronald A. Pepin, Ph.D. (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S |
|
| November 10, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on November 10, 2025 (the “Effective Date”), between Teri Lawver (the “Executive”) and Celldex Therapeutics, Inc., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). 1.PURPOSE. The Company desires to avail itself of the services of t |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exac |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2025 |
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and strong efficacy regardless of baseline IgE levels Positive Phase 2 |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 19, 2025 |
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) Exhibit 99.1 Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) · Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract · Profound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE · Favorable saf |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact nam |
|
| August 7, 2025 |
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated from Phase 2 studies of barzolvolimab in EoE an |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 As filed with the Securities and Exchange Commission on June 6, 2025 Registration No. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2025 |
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors Exhibit 99.1 Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors HAMPTON, N.J., June 6, 2025 - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. “We are excited to welcome Denice to the Celldex Board of Directors,” said Anthony Marucci, Co-founder, President and Chief Executive Officer |
|
| June 6, 2025 |
Amendment No. 3 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan Exhibit 10.1 AMENDMENT No. 3 TO CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Dated: April 10, 2025 This Agreement amends the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves to the Board of Directors (“Board”) |
|
| June 6, 2025 |
Calculation of Filing Fee Tables S-8 Celldex Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 2,000,000 $ 40,030,000.00 0.0001531 $ 6,128.59 Total Offeri |
|
| May 8, 2025 |
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update Strong execution and progress across pipeline with multiple key data read outs expected in 2025 Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under development Phase 2 EOE study enrollment compl |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na |
|
| April 21, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 21, 2025 |
28AUG200910022691 Proxy Statement for 2025 Annual Meeting 2024 Annual Report on Form 10-KNoticeofAnnualMeetingofStockholders DateandTime VirtualMeeting RecordDate June5,2025 at 9:00a. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exa |
|
| February 27, 2025 |
Celldex Therapeutics, Inc. Insider Trading Policy Exhibit 19.1 INSIDER TRADING POLICY (Revised February 12, 2025 ) This Insider Trading Policy (this “Policy”) of Celldex Therapeutics, Inc. (the “Company” or “Celldex”) is designed to prevent insider trading or allegations of insider trading, protect the Company’s reputation for integrity and ethical conduct and to assist Insiders (as defined below) in complying with their obligations under the fed |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 27, 2025 |
Exhibit 10.17 FOURTH AMENDMENT TO LEASE AGREEMENT This Fourth Amendment to Lease Agreement (this “Amendment”) is made and entered into as of October 30, 2024 (“Effective Date”), by and between PERRYVILLE SPE, LLC, a limited liability company (“Landlord”), and CELLDEX THERAPEUTICS, INC. (“Tenant”). W I T N E S S E T H: WHEREAS, Landlord’s predecessor-in-interest, Crown Perryville, LLC., and Tenant |
|
| February 27, 2025 |
Subsidiaries of Celldex Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100% |
|
| February 27, 2025 |
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development Phase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in Phase 2 PN study Celldex’s first bispecific for inflammatory diseases, CDX- |
|
| February 27, 2025 |
Exhibit 10.12 ELEVENTH AMENDMENT TO LEASE This ELEVENTH AMENDMENT TO LEASE (this “Amendment”) is made as of the 1st day of December, 2024, (the “Effective Date”) by and between UNIVERSITY OF MASSACHUSETTS DARTMOUTH, an institution of Higher Education of the Commonwealth of Massachusetts, with an address of 285 Old Westport Rd. North Dartmouth Massachusetts 02747 (“Landlord”) and CELLDEX THERAPEUTI |
|
| February 12, 2025 |
EX-99 2 exhibit99.txt Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Life Limited BlackRock Advisors, LLC Aperio Group, LLC BlackRock (Netherlands) B.V. BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Managem |
|
| November 14, 2024 |
SC 13G/A 1 p24-3192sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this stat |
|
| November 14, 2024 |
CLDX / Celldex Therapeutics, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 eventidecelldex-sc13g.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of th |
|
| November 14, 2024 |
CLDX / Celldex Therapeutics, Inc. / Point72 Asset Management, L.P. Passive Investment SC 13G/A 1 p24-3151sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 13, 2024 |
CLDX / Celldex Therapeutics, Inc. / Polar Capital Holdings Plc Passive Investment SC 13G/A 1 polar-cldx093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CELLDEX THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $.001 (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 12, 2024 |
CLDX / Celldex Therapeutics, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 CELLDEX THERAPEUTICS INC COMMON STOCK Cusip #15117B202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #15117B202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,022,607 Item 6: 0 Item 7: 6,024,416 Item 8: 0 It |
|
| November 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Celldex Therapeutics, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d- |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exac |
|
| November 6, 2024 |
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development All primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 week treatment data in landmark, global Phase 2 CSU study demonstrated deepening of |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact nam |
|
| August 8, 2024 |
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 CSU studies initiated July 2024 Positive topline Phase 2 CIndU 12 week data reported July 2024 supporting Phase 3 advancement 52 week Phase 2 CSU data and full 12 week Phase 2 CIndU data to be reported 2H 2024 Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to start YE 2024 |
|
| June 14, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Celldex Therapeutics, Inc. |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| June 14, 2024 |
Amendment No. 2 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan Exhibit 10.1 AMENDMENT No. 2 TO CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Dated: April 12, 2024 This Amendment amends the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves to the Board of Directors (“Board”) |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na |
|
| May 6, 2024 |
EXHIBIT 99.1 Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 - - Phase 2 PN study initiated; |
|
| April 25, 2024 |
28AUG200910022691 Proxy Statement for 2024 Annual Meeting 2023 Annual Report on Form 10-KCELLDEXTHERAPEUTICS,INC. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Celldex Therapeutics, Inc. |
|
| March 1, 2024 |
Celldex Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Celldex Therapeutics Announces Proposed Public Offering of Common Stock HAMPTON, N.J., February 28, 2024 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant |
|
| March 1, 2024 |
Exhibit 1.1 CELLDEX THERAPEUTICS, INC. 8,520,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement February 29, 2024 LEERINK PARTNERS LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Ladies and G |
|
| March 1, 2024 |
Financial Statements and Exhibits, Other Events, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commi |
|
| March 1, 2024 |
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock Exhibit 99.2 Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock HAMPTON, N.J., February 29, 2024 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the |
|
| March 1, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-275300 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2023) 8,520,000 Shares COMMON STOCK We are offering 8,520,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CLDX.” The last reported sale price of our common stock on February 29, |
|
| February 28, 2024 |
TABLE OF CONTENTS The information in this preliminary prospectus is not complete and may be changed. |
|
| February 26, 2024 |
Celldex Therapeutics, Inc. Compensation Recovery Policy Exhibit 97 CELLDEX THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on September 14, 2023, and effective as of December 1, 2023) 1. Purpose Celldex Therapeutics, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this comm |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exa |
|
| February 26, 2024 |
Exhibit 1.1 CELLDEX THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement February 26, 2024 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as fol |
|
| February 26, 2024 |
Subsidiaries of Celldex Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100% |
|
| February 26, 2024 |
Up to $300,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-275300 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2023) Up to $300,000,000 Common Stock In accordance with the terms of the Controlled Equity OfferingSM sales agreement, dated February 26, 2024, or the Sales Agreement, we entered into with Cantor Fitzgerald & Co., or Cantor, we may offer and sell shares of our co |
|
| February 26, 2024 |
EXHIBIT 99.1 Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 - - Phase 2 PN s |
|
| February 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Celldex Therapeutics, Inc. |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2024 |
SC 13G/A 1 p24-0389sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this state |
|
| February 14, 2024 |
CLDX / Celldex Therapeutics, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 celldexthera-eventide13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Celldex Therapeutics, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Fili |
|
| February 14, 2024 |
SC 13G/A 1 p24-0668sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State |
|
| February 14, 2024 |
SC 13G 1 cldx21424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the approp |
|
| February 13, 2024 |
CLDX / Celldex Therapeutics, Inc. / Polar Capital Holdings Plc Passive Investment SC 13G 1 polar-cldx123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CELLDEX THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $.001 (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 13, 2024 |
CLDX / Celldex Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0562-celldextherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Celldex Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 15117B202 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| February 9, 2024 |
CLDX / Celldex Therapeutics, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 CELLDEX THERAPEUTICS INC COMMON STOCK Cusip #15117B202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #15117B202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,005,163 Item 6: 0 Item 7: 7,050,409 Item 8: 0 It |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 26, 2024 |
CLDX / Celldex Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us15117b2025012624.txt us15117b2025012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Celldex Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 15117B202 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 20, 2023 |
SC 13G 1 p23-2861sc13g.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) November 10, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| November 20, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p23-2861exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| November 8, 2023 |
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Celldex Therapeutics Announces Pricing of Public Offering of Common Stock November 7, 2023 HAMPTON, N.J., November 7, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public offering price of $27.00 per share. In connection with the |
|
| November 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Celldex Therapeutics, Inc. |
|
| November 8, 2023 |
Celldex Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Celldex Therapeutics Announces Proposed Public Offering of Common Stock November 7, 2023 HAMPTON, N.J., November 7, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant th |
|
| November 8, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-275300 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 3, 2023) 7,425,000 Shares COMMON STOCK We are offering 7,425,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CLDX.” The last reported sale price of our common stock on November 7, 2 |
|
| November 8, 2023 |
Exhibit 1.1 CELLDEX THERAPEUTICS, INC. 7,425,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement November 7, 2023 JEFFERIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Cell |
|
| November 8, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2023 |
TABLE OF CONTENTS The information in this preliminary prospectus is not complete and may be changed. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis |
|
| November 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Celldex Therapeutics, Inc. |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 3, 2023 As filed with the Securities and Exchange Commission on November 3, 2023 Registration No. |
|
| November 2, 2023 |
EXHIBIT 99.1 Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch - HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a cor |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exac |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact nam |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2023 |
EXHIBIT 99.1 Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 - - First patient dosed in Phase 2 EoE study - HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 |
|
| June 21, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Celldex Therapeutics, Inc. |
|
| June 21, 2023 |
As filed with the Securities and Exchange Commission on June 21, 2023 As filed with the Securities and Exchange Commission on June 21, 2023 Registration No. |
|
| June 15, 2023 |
Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended June 15, 2023) Exhibit 10.1 AMENDMENT TO CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Dated: April 11, 2023 This Amendment amends the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves to the Board of Directors (“Board”) of Ce |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) April 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na |
|
| May 4, 2023 |
EXHIBIT 99.1 Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment completion expected in Q3 2023 - - Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 - - Phase 2 EoE study expected to initiate in June 2023 - HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| April 25, 2023 |
28AUG200910022691 Proxy Statement for 2023 Annual Meeting 2022 Annual Report on Form 10-KCELLDEXTHERAPEUTICS,INC. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 28, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock summarizes the material terms and provisions of our common stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our Third Restated Certifica |
|
| February 28, 2023 |
Subsidiaries of Celldex Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100% |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2023 |
EXHIBIT 99.1 Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update - Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 - HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended Decem |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exa |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 21, 2023 |
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors Exhibit 99.1 Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors HAMPTON, N.J., February 16, 2023 - Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors. “We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company’s trajectory,” said Anthony |
|
| February 14, 2023 |
SC 13G/A 1 p23-0592sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this state |
|
| February 14, 2023 |
CLDX / Celldex Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 brhc10047893sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Celldex Therapeutics, Inc. (Name of Issuer) Common stock, $.001 par value per share |
|
| February 9, 2023 |
CLDX / Celldex Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0540-celldextherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Celldex Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 15117B202 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| February 9, 2023 |
CLDX / Celldex Therapeutics, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 CELLDEX THERAPEUTICS INC COMMON STOCK Cusip #15117B202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #15117B202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,020,407 Item 6: 0 Item 7: 7,064,974 Item 8: 0 It |
|
| February 6, 2023 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 1, 2023 |
CLDX / Celldex Therapeutics, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING CELLDEX THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 15117B202 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS |
|
| February 1, 2023 |
CLDX / Celldex Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us15117b2025013123.txt us15117b2025013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Celldex Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 15117B202 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 9, 2022 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION FOURTH AMENDED AND RESTATED LICENSE AGREEMENT THIS FOURTH AMENDED AND RESTATED LICENSE AGREEMENT (this ?AGREEMENT?), dated as of June 29, 2022 (the ?FOURTH AMENDMENT EFFECTIVE DATE?), by and bet |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 9, 2022 |
Second Amended and Restated By-Laws of Celldex Therapeutics, Inc., dated November 3, 2022 ? Exhibit 3.1 ? SECOND AMENDED AND RESTATED BY-LAWS OF CELLDEX THERAPEUTICS, INC. ? as of November 3, 2022 ? ARTICLE I OFFICES ? SECTION 1. REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Third Restated Certificate of Incorporation of the Corporation (as amended and/or restated from time to time, the ?Certificate of Incorporation?). ? SECTION 2. OTHER OFFICES. The |
|
| November 9, 2022 |
EXHIBIT 99.1 Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Multiple clinical-stage programs on track for data updates in upcoming months - HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. ?Celldex continued t |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2022 |
Exhibit 10.2 TENTH AMENDMENT TO LEASE This TENTH AMENDMENT TO LEASE (this ?Amendment?) is made as of the 1st day of August, 2022, (the ?Effective Date?) by and between UNIVERSITY OF MASSACHUSETTS DARTMOUTH, an institution of Higher Education of the Commonwealth of Massachusetts, with an address of 285 Old Westport Rd. North Dartmouth Massachusetts 02747 (?Landlord?) and CELLDEX THERAPEUTICS, INC. |
|
| August 8, 2022 |
Exhibit 10.3 THIRD AMENDMENT OF LEASE THIS THIRD AMENDMENT OF LEASE, dated as of May 23, 2022, between PERRYVILLE SPE LLC (?Landlord?), and CELLDEX THERAPEUTICS, INC. (?Tenant?). W I T N E S S E T H: WHEREAS, Landlord's predecessor-in-interest, Crown Perryville, LLC., and Tenant entered into that certain Lease dated as of May 1, 2013 (the ?Original Lease?) in the building known as Perryville Ill a |
|
| August 8, 2022 |
EXHIBIT 99.1 Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results fo |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 18, 2022 |
Exhibit 10.1 CONFIDENTIAL SETTLEMENT AGREEMENT AND MUTUAL RELEASE This Confidential Settlement Agreement and Mutual Release (the ?Agreement?) is entered into effective as of July 15, 2022 (the ?Effective Date?) by and among Celldex Therapeutics, Inc. (?Celldex?) and Shareholder Representative Services LLC (?SRS?), in its capacity as the Stockholders representative under the Merger Agreement (defin |
|
| July 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| June 23, 2022 |
Exhibit 10.1 BINDING SETTLEMENT TERM SHEET This BINDING TERM SHEET (the ?Term Sheet?), is entered into as of June 20, 2022 (?Effective Date?) by and between Shareholder Representatives Services LLC (?SRS?), solely in its capacity as the Stockholders representative under the Merger Agreement (defined below), and Celldex Therapeutics, Inc. (?Celldex?). WHEREAS, on November 1, 2016, the parties enter |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| June 10, 2022 |
CLDX / Celldex Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Celldex Therapeutics, Inc. (Name of Issuer) Common stock, $.001 par value per share (Title of Class of Securities) 15117B202 (CUSIP Number) May 3 |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na |
|
| May 5, 2022 |
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. ?This quarter, we continued to focus on advancing our clinical programs and are on track to report data fro |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 26, 2022 |
DEF 14A 1 tm223422-1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2022 |
Subsidiaries of Celldex Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. ? ? ? ? ? ? Jurisdiction of Ownership Name ? Organization ? Percentage Celldex Therapeutics Switzerland GmbH ? Switzerland ? 100% ? |
|
| February 28, 2022 |
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update EXHIBIT 99.1 Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update CSU Phase 1b multi-dose data expected in July CDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022 Expanded development of CDX-0159 into Eosinophilic Esophagitis (EoE) Well capitalized with $408.3 mil |
|
| February 14, 2022 |
CLDX / Celldex Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Celldex therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value par value per share, of Celldex Ther |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2022 |
CLDX / Celldex Therapeutics, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING CELLDEX THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 15117B202 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE |
|
| February 9, 2022 |
CLDX / Celldex Therapeutics, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 1 CELLDEX THERAPEUTICS INC COMMON STOCK Cusip #15117B202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #15117B202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 990,130 Item 6: 0 Item 7: 6,999,580 Item 8: 0 Item 9: 6,999,580 Item 11 |
|
| February 9, 2022 |
CLDX / Celldex Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Celldex Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 15117B202 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| February 4, 2022 |
CLDX / Celldex Therapeutics, Inc. / BlackRock Inc. Passive Investment us15117b2025020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Celldex Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 15117B202 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 28, 2022 |
Amendment No. 1 to the Amended and Restated By-Laws of Celldex Therapeutics, Inc. Exhibit 3.1 AMENDMENT NO. 1 TO The Amended and Restated by-laws OF Celldex Therapeutics, Inc. This Amendment (this ?Amendment?) to the Amended and Restated By-Laws (the ?By-Laws?) of Celldex Therapeutics, Inc., a Delaware corporation (the ?Corporation?), has been adopted and approved by the Board of Directors of the Corporation on January 25, 2022 and is effective as of January 25, 2022. Capitaliz |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 15117B103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 15117B103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exac |
|
| November 9, 2021 |
Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “During the third quarter we reported compelling data from our ongo |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 12, 2021 |
CLDX / Celldex Therapeutics, Inc. / FMR LLC Passive Investment SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 CELLDEX THERAPEUTICS INC COMMON STOCK Cusip #15117B202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #15117B202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 421,707 Item 6: 0 Item 7: 5,615,333 Item 8: 0 Item |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2021 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
EXHIBIT 99.1 Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 - - Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021 - HAMPTON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) |
|
| July 15, 2021 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-249917? CALCULATION OF REGISTRATION FEE ? ? Title of each class of securities to be registered ? ? ? Amount to be registered ? ? ? Proposed maximum offering price per share ? ? ? Proposed maximum aggregate offering price ? ? ? Amount of registration fee ? Common Stock, par value $0.001 per share ? ? ? 6,845,238(1) ? ? ? $42.00 |
|
| July 14, 2021 |
? Exhibit 1.1 ? CELLDEX THERAPEUTICS, INC. 5,952,381 Shares of Common Stock (par value $0.001 per share) ? Underwriting Agreement ? July 13, 2021 ? JEFFERIES LLC SVB LEERINK LLC As Representatives of the several Underwriters listed in Schedule A hereto ? c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 ? c/o SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 ? |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| July 14, 2021 |
Exhibit 99.1 Celldex Therapeutics Announces Proposed Public Offering of Common Stock HAMPTON, N.J., July 12, 2021 (GLOBE NEWSWIRE) ? Celldex Therapeutics, Inc. (?Celldex? or the ?Company?) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $175 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the un |
|
| July 14, 2021 |
Exhibit 99.2 Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) ? Celldex Therapeutics, Inc. (?Celldex? or the ?Company?) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commission |
|
| July 12, 2021 |
SUBJECT TO COMPLETION, DATED JULY 12, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commission |
|
| July 1, 2021 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Anthony S. Marucci (the ?Executive?) and CELLDEXTHERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHE |
|
| July 1, 2021 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), between Sam Martin (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHEREAS |
|
| July 1, 2021 |
EX-10.6 7 tm2120284d1ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 1, 2021 (the “Effective Date”), between Margo Heath-Chiozzi, M.D. (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be |
|
| July 1, 2021 |
Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Ronald A. Pepin, Ph.D. (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H |
|
| July 1, 2021 |
Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Sarah Cavanaugh (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHERE |
|
| July 1, 2021 |
Exhibit 10.10 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), between Freddy Jimenez (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WH |
|
| July 1, 2021 |
Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Elizabeth Crowley (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHE |
|
| July 1, 2021 |
EX-10.3 4 tm2120284d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 1, 2021 (the “Effective Date”), between Tibor Keler, Ph.D. (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred |
|
| July 1, 2021 |
Exhibit 10.8 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Richard Wright, Ph.D. (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). WHEREAS, the Executi |
|
| July 1, 2021 |
EX-10.9 10 tm2120284d1ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 1, 2021 (the “Effective Date”), between Diane Young, MD (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred |
|
| June 17, 2021 |
Celldex Therapeutics, Inc. 2021 Plan Form of Nonqualified Stock Option Grant Agreement Exhibit 10.4 NONQUALIFIED STOCK OPTION GRANT AGREEMENT CELLDEX THERAPEUTICS, INC. This Stock Option Grant Agreement (the ?Grant Agreement?) is made and entered into effective on the Date of Grant set forth in Exhibit A (the ?Date of Grant?) by and between Celldex Therapeutics, Inc., a Delaware corporation (the ?Company?), and the individual named in Exhibit A hereto (the ?Optionee?). WHEREAS, the |
|
| June 17, 2021 |
Celldex Therapeutics, Inc. 2021 Plan Form of Restricted Stock Unit Award Agreement Exhibit 10.5 RESTRICTED STOCK UNIT AWARD AGREEMENT CELLDEX THERAPEUTICS, INC. This Restricted Stock Unit Award Agreement (the ?Agreement? or ?Award Agreement?), dated as of the ?Award Date? set forth in the attached Exhibit A, is entered into between Celldex Therapeutics, Inc., a Delaware corporation (the ?Company?), and the individual named in Exhibit A hereto (the ?Awardee?). WHEREAS, the Compan |
|
| June 17, 2021 |
Celldex Therapeutics, Inc. 2021 Plan Form of Restricted Stock Award Agreement Exhibit 10.2 RESTRICTED STOCK AWARD AGREEMENT CELLDEX THERAPEUTICS, INC. This Restricted Stock Award Agreement (the ?Agreement?), dated as of the ?Award Date? set forth in the attached Exhibit A (the ?Award Date?), is entered into between Celldex Therapeutics, Inc., a Delaware corporation (the ?Company?), and the individual named in Exhibit A hereto (the ?Awardee?). WHEREAS, the Company desires to |
|
| June 17, 2021 |
Celldex Therapeutics, Inc. 2021 Plan Form of Incentive Stock Option Grant Agreement Exhibit 10.3 INCENTIVE STOCK OPTION GRANT AGREEMENT CELLDEX THERAPEUTICS, INC. This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”). WHEREAS, the Com |
|
| June 17, 2021 |
Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan Exhibit 10.1 CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN 1. Establishment and Purpose 1.1 The purpose of the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the ?Plan?) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in the developmen |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
|
| June 16, 2021 |
As filed with the Securities and Exchange Commission on June 16, 2021 S-8 1 tm2119432d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on June 16, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3191702 (State or other jurisdiction of inco |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 6, 2021 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2021 |
Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update HAMPTON, N.J., May 06, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “We are very encouraged by the recently reported positive interim result |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant a |
|
| April 27, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| March 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 29, 2021 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 29, 2021 |
10-K 1 tm211037-110k.htm 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 |
|
| March 29, 2021 |
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020. “Celldex made significant progress across our pipeline in 2020 and today continued this momentum with th |
|
| March 29, 2021 |
Subsidiaries of Celldex Therapeutics, Inc. EX-21.1 2 tm211037d1ex21x1.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100% |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 15117B103 (CUSIP Number) February 22, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value par value per share, of Celldex Ther |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 1 under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Celldex Therapeutics, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties he |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Numbe |
|
| February 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CELLDEX THERAPEUTICS, INC. - (Name of Issuer) Common Stock, par value $.001 - (Title of Class of Securities) 15117B202 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 4, 2021 |
EX-10.1 2 tm2039684d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 1, 2021 (the “Effective Date”), between Freddy Jimenez (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E T |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 1, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commiss |
|
| January 4, 2021 |
Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel EX-99.1 3 tm2039684d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel HAMPTON, N.J., January 4, 2021 - Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel, effective January 1, 2021. Over the span of a 30 year career in the biopharmace |
|
| November 6, 2020 |
S-3ASR 1 tm2034702-1s3asr.htm S-3ASR TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 6, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELLDEX THERAPUETICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j |
|
| November 6, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registra |
|
| November 5, 2020 |
Celldex Provides Corporate Update and Reports Third Quarter 2020 Results EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Third Quarter 2020 Results HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020. “In the third quarter, building on the compelling CDX-0159 data presented at EAACI, we initiated two Phase 1b studies in chronic |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 5, 2020 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 22, 2020 |
CLDX / Celldex Therapeutics, Inc. / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15117B202 (CUSIP Number) June 16, 20201 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| August 18, 2020 |
8-K 1 tm2028934-18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisd |
|
| August 6, 2020 |
Exhibit 10.1 July 1, 2020 Attn: Michael LaGrassa Associate Vice Chancellor of Administrative Operations & Compliance UMass Dartmouth 285 Old Westport Road North Dartmouth, MA 02747 Dear Michael, Pursuant to Section 2.3 of the lease between UMass Dartmouth and Celldex Therapeutics (“Celldex”), as amended, (the “Lease”), Celldex is hereby providing notice of its exercise of its first two (2) year ex |
|
| August 6, 2020 |
EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Second Quarter 2020 Results -Conference Call and Webcast today at 4:30pm ET- HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company will host a conference call at 4:30 p.m. ET today to provide an update |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k080620.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2020 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of |
|
| July 24, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) July 14, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t |
|
| June 26, 2020 |
As filed with the Securities and Exchange Commission on June 26, 2020 Registration No. |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number |
|
| June 26, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 26, 2020 with respect to the shares of Common Stock of Celldex Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under |
|
| June 19, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Celldex Therapeutics, Inc. |
|
| June 19, 2020 |
CLDX / Celldex Therapeutics, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 18, 2020 |
CLDX / Celldex Therapeutics, Inc. / Ikarian Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) June 10, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| June 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio |
